We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+20.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$215M
AUM Growth
+$41.5M
Cap. Flow
+$31.8M
Cap. Flow %
14.78%
Top 10 Hldgs %
55.52%
Holding
68
New
22
Increased
11
Reduced
19
Closed
11
Avg Time Held Equity + Options
0.2 years
Top 10 Avg Time Held Equity + Options
0.1 years
Top 20 Avg Time Held Equity + Options
0.2 years
Avg Time Held Equity only
0.2 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.2 years

Top Buys

Rank Stock Value
1
QCP
Quality Care Properties, Inc.
QCP
+$11.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$10.2M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$8.59M
4
GSK icon
GSK
GSK
+$8.44M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$6.04M

Top Sells

Rank Stock Value
1
ARRY icon
Array Biopharma Inc
ARRY
+$14.1M
2
EHTH icon
eHealth
EHTH
+$4.18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$4.01M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$2.62M
5
PBYI icon
Puma Biotechnology
PBYI
+$2.38M

Sector Composition

Rank Sector Weight
1 Healthcare 75.31%
2 Real Estate 9.99%
3 Miscellaneous 7.87%
4 Industrials 6.33%
5 Financials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IVC
26
DELISTED
Invacare Corporation
IVC
$1.74M 0.81%
99,902
+2,600
+3% +$45.8K
2017 Q4
1 quarter
DCPH icon
27
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.71M 0.79%
+85,090
New +$2.16M
2018 Q1
0 quarters
ASND icon
28
Ascendis Pharma A/S
ASND
$14.8B
$1.57M 0.73%
24,054
+11,936
+98% +$671K
2017 Q4
1 quarter
PBYI icon
29
Puma Biotechnology
PBYI
$507M
$1.56M 0.72%
22,924
-31,725
-58% -$2.38M
2017 Q4
1 quarter
CTRE icon
30
CareTrust REIT
CTRE
$8.64B
$1.47M 0.68%
108,264
-30,000
-22% -$444K
2017 Q4
1 quarter
ELV icon
31
Elevance Health
ELV
$92.9B
$1.32M 0.61%
+6,000
New +$1.41M
2018 Q1
0 quarters
MDCO
32
DELISTED
Medicines Co
MDCO
$1.3M 0.6%
+39,317
New +$1.23M
2018 Q1
0 quarters
IOVA icon
33
Iovance Biotherapeutics
IOVA
$6.17B
$1.1M 0.51%
+65,000
New +$984K
2018 Q1
0 quarters
HAE icon
34
Haemonetics
HAE
$5.38B
$1.07M 0.5%
+14,646
New +$1M
2018 Q1
0 quarters
CNC icon
35
Centene
CNC
$34.2B
$1.07M 0.5%
+20,000
New +$1.04M
2018 Q1
0 quarters
EHTH icon
36
eHealth
EHTH
$18.8M
$1.07M 0.5%
74,546
-254,009
-77% -$4.18M
2017 Q4
1 quarter
EPZM
37
DELISTED
Epizyme, Inc
EPZM
$1.02M 0.47%
+57,449
New +$970K
2018 Q1
0 quarters
MGLN
38
DELISTED
Magellan Health Services, Inc.
MGLN
$994K 0.46%
9,282
– –
2017 Q4
1 quarter
GBT
39
DELISTED
Global Blood Therapeutics, Inc.
GBT
$860K 0.4%
17,800
-21,000
-54% -$1.17M
2017 Q4
1 quarter
ARNA
40
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$826K 0.38%
+20,900
New +$813K
2018 Q1
0 quarters
ALGN icon
41
Align Technology
ALGN
$10.5B
$753K 0.35%
3,000
-1,000
-25% -$257K
2017 Q4
1 quarter
AMRN icon
42
Amarin Corp
AMRN
$239M
$753K 0.35%
+12,500
New +$928K
2018 Q1
0 quarters
IRMD icon
43
iRadimed
IRMD
$1.13B
$735K 0.34%
51,059
– –
2017 Q4
1 quarter
AFMD icon
44
DELISTED
Affimed
AFMD
$716K 0.33%
+38,686
New +$730K
2018 Q1
0 quarters
BCRX icon
45
BioCryst Pharmaceuticals
BCRX
$1.99B
$711K 0.33%
148,959
-49,360
-25% -$254K
2017 Q4
1 quarter
DVAX icon
46
DELISTED
Dynavax Technologies
DVAX
$596K 0.28%
+30,000
New +$518K
2018 Q1
0 quarters
ABUS icon
47
Arbutus Biopharma
ABUS
$836M
$587K 0.27%
117,495
+10,000
+9% +$53K
2017 Q4
1 quarter
ALBO
48
DELISTED
Albireo Pharma Inc
ALBO
$587K 0.27%
+18,029
New +$607K
2018 Q1
0 quarters
MLNT
49
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$569K 0.26%
+15,367
New +$1.01M
2018 Q1
0 quarters
FOMX
50
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$551K 0.26%
+107,500
New +$647K
2018 Q1
0 quarters
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Eversept Partners held 68 positions worth $215M, up 24% from $174M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $31.8M of net new capital in Q1 2018, opening 22 new positions and adding to 11 existing holdings. Its largest new stake was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 75% a quarter earlier, followed by Real Estate and Miscellaneous.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $14.1M trimmed.

  • Eversept Partners's largest Q1 2018 buy was Alnylam Pharmaceuticals: 78,893 shares worth $9.4M.
  • Eversept Partners added most to Quality Care Properties, Inc. in Q1 2018, an estimated $11.7M increase.
  • Eversept Partners's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $14.1M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q1 2018, selling an estimated $4.01M.
  • Eversept Partners's ten largest holdings make up 56% of its $215M portfolio in Q1 2018.
  • Eversept Partners opened 22 new positions and closed 11 in Q1 2018.
  • Eversept Partners's portfolio value rose 24% quarter-over-quarter to $215M.

Based on Eversept Partners's 13F filing for Q1 2018, filed 14 May 2018.